Prostate Cancer Theranostics

Steven P. Rowe, Mohammad S. Sadaghiani, Rudolf A. Werner, Takahiro Higuchi, Thorsten Derlin, Lilja B. Solnes, Martin G. Pomper

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A theranostic can broadly be defined as an agent used for disease detection and therapy. Here we focus on imaging-based theranostics. While the concept has been in practice for over 80 years in the case of radioiodine, recent advances in the discovery of targeted, high-affinity scaffolds, the rediscovery of previously obscure radionuclides for therapy, improvements in chelation chemistry, and a deeper understanding of radiation dosimetry have contributed to a renaissance in the field. Also contributing is the lack of safe and effective therapy for metastatic disease, with chemotherapy or even immunotherapy often not particularly effective, as for metastatic castration-resistant prostate cancer which carries a 1-year survival of ~40% once within bone. The availability of small-molecule scaffolds that target the prostate-specific membrane antigen, once pharmacokinetically optimized and outfitted with particle-emitting radionuclides, has also helped to revitalize theranostics, in part because of the high incidence of mCRPC. Participation in this area has markedly increased recently, with industry becoming involved, leading to likely FDA approval of several such agents in the near-term. Nevertheless, further work is needed regarding prospective trials, which will define whether theranostics can substantially extend the lives of men suffering from mCRPC.

Original languageEnglish
Title of host publicationMolecular Imaging
Subtitle of host publicationPrinciples and Practice
PublisherElsevier
Pages1117-1130
Number of pages14
ISBN (Electronic)9780128163863
ISBN (Print)9780128163870
DOIs
Publication statusPublished - Jan 1 2021
Externally publishedYes

Keywords

  • Alpha-particle
  • Auger electron
  • Beta-particle
  • Bombesin
  • Companion diagnostic
  • Endoradiotherapy
  • mCRPC
  • Positron emission tomography
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Prostate Cancer Theranostics'. Together they form a unique fingerprint.

Cite this